Streetbeat News

Products Services

DRCT

IBIO

NVCR

IBio shares surged 119% following a collaboration with AstralBio on AI-driven antibodies for obesity and cardiometabolic diseases. Direct Digital Holdings' shares plummeted by 49% due to disappointing Q4 financial results. Novocure's stock rose 42% after its METIS Phase 3 trial for brain metastases from non-small cell lung cancer met its primary endpoint.

Portfolio Pulse from ryanfaloona@benzinga.com

March 27, 2024 | 12:31 pm

CYBR

CyberArk has introduced a new identity-centric secure browser, designed to enhance security, privacy, and productivity controls across both managed and unmanaged workforce devices.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:28 pm

HOTH

NVDA

Hoth Therapeutics' subsidiary, Merveille.ai, has filed a patent for an obesity treatment and is preparing for clinical trials. Additionally, Merveille.ai has joined the Nvidia Developer Program, indicating a potential collaboration or utilization of Nvidia's technology in their research or development processes.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:28 pm

SSYS

Stratasys has formed a Customer Advisory Board comprising industry leaders to promote the advancement of additive manufacturing for large-scale production. This initiative marks a significant step by Stratasys in engaging with industry experts to shape the future of 3D printing technologies.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:18 pm

COST

CVS

TGT

On CNBC's 'Halftime Report Final Trades,' CVS Health Corporation (CVS) was highlighted for its strong comeback amid Amazon Pharmacy's expansion. Costco (COST) was favored despite missing revenue estimates, showing a 5.7% year-over-year sales increase. Target (TGT) was recommended after reporting a revenue growth of 1.7% year-on-year, despite a decline in comparable sales. CVS reaffirmed its 2024 earnings guidance, while Amazon launched Same-Day Delivery in select areas.

Portfolio Pulse from Avi Kapoor

March 27, 2024 | 12:14 pm

CART

Instacart (NASDAQ:CART) has launched the Instacart Developer Platform (IDP), a new API program designed to integrate Instacart's online grocery platform functionalities into third-party websites and apps. This initiative aims to enhance digital experiences across various sectors by providing same-day fulfillment, access to a rich item catalog, and real-time inventory updates from local retailers. The platform is expected to benefit developers and companies in food, health, wellness, and lifestyle sectors by enabling seamless integration of grocery shopping into their digital offerings.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:10 pm

PACB

PacBio (NASDAQ:PACB) has been selected by the University of Tartu, host of Estonia's National Biobank, to sequence 10,000 whole human genomes using the Revio HiFi sequencing system. This initiative, funded by the European Commission and the Estonian government, aims to advance personalized medicine and contribute to the EU's 1+ Million Genomes initiative. The project will explore genetics related to various health conditions and responses to medications, with the potential to significantly impact healthcare research and innovation.

Portfolio Pulse from Happy Mohamed

March 27, 2024 | 12:10 pm

MDXG

The FDA issued a determination letter to MiMedx, indicating that Axiofill, the company's product, does not meet the regulatory classification requirements for a human cell, tissue, or cellular or tissue-based product (HCT/P).

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:09 pm

ALGS

Aligos Therapeutics, Inc. (NASDAQ:ALGS) announced its participation in the 33rd Annual Meeting of the APASL 2024 with presentations on ALG-055009 and ALG-000184 Phase 1 studies. ALG-055009 showed favorable effects in hyperlipidemic subjects, while ALG-000184 demonstrated potent antiviral activity in CHB patients. The company remains optimistic about the potential of these compounds in treating liver and viral diseases.

Portfolio Pulse from Happy Mohamed

March 27, 2024 | 12:07 pm

ACN

Accenture (NYSE:ACN) has invested in Sanctuary AI, a company developing AI-powered humanoid robots designed to work alongside humans in various industries. Sanctuary AI's robot, Phoenix, has demonstrated the ability to perform over 100 tasks with human-like dexterity. This investment is part of Accenture Ventures' Project Spotlight, aiming to bridge innovation gaps by connecting startups with Accenture's global client base. The move aligns with Accenture's vision of integrating human-centric technology in the workforce, as highlighted in their Technology Vision 2024 report.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:03 pm